French Project to Tackle Antibiotic Resistance with Biotech and Economics

A team of French organizations led by the biotech firm Antabio has launched a €17M project to deploy therapeutic, diagnostic, and economic innovations in the battle against antibiotic resistance.

The project, dubbed ARPEGE, involves four partners covering a variety of disciplines: the antibiotics developer Antabio; the diagnostics heavyweight bioMérieux; the university hospital group Hospices Civils de Lyon (HCL) paired with the International Centre for Infectious Disease Research; and the Toulouse School of Economics (TSE). The total budget of the four-year project is expected to be €17M, with almost €9M already provided by the French government.